Summary
Cardinal Health, Inc. (CAH) announced a significant strategic move through the acquisition of The Harvard Drug Group on June 5, 2015. This acquisition is expected to enhance Cardinal Health's position in the pharmaceutical distribution and services market. The company also provided preliminary guidance for its fiscal year 2016 non-GAAP diluted earnings per share from continuing operations, signaling confidence in its future performance and integration of the new business. Investors should note that the company has made these announcements in conjunction with its Dublin Day investor/analyst meeting, where further details will be discussed. The accompanying news release and Q&A document provide additional context on the acquisition and financial outlook. The company is also making presentation slides and an audio replay available online for broader investor access.
Key Highlights
- 1Acquisition of The Harvard Drug Group announced.
- 2Preliminary fiscal year 2016 non-GAAP diluted EPS expectations provided.
- 3Acquisition is expected to strengthen Cardinal Health's market position.
- 4Details of the acquisition and financial outlook disclosed via news release (Exhibit 99.1).
- 5Transaction-specific questions and answers are available (Exhibit 99.2).
- 6Company is hosting a Dublin Day investor/analyst meeting on June 5, 2015.
- 7Webcast and presentation slides will be available on the investor relations website.